iktos
Created in 2016
Up & running (A)
Existing signals show a regular activitySocial networks
1,122 115 8,591Activities
Technologies
Entity types
Location
65 Rue de Prony, 75017 Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 81
SIREN
823189279Engaged catalyst
50
0 0Added in Motherbase
6 years, 6 months ago
Value proposition
Artificial intelligence for new drug design
We are a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms MakyaTM for generative drug design and SpayaTM for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI).
artificial intelligence, medicinal chemistry, chemoinformatics, machine learning, deep learning, molecular modeling, CADD, MPO, de novo drug design, drug design, inverse-QSAR, QSAR, lead optimization, Robotics, and AutomationOriginal language
Artificial intelligence for new drug design
We are a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms MakyaTM for generative drug design and SpayaTM for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI).
Iktos
https://iktos.ai/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 28 Feb 2025 | | |
 Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Not capitalistic Partnership Not event 30 Apr 2019 26 Nov 2024 | | |
 Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 29 Jan 2019 | | |
 Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 5 Nov 2020 31 Oct 2024 | | |
 Serena Startup accelerator & VC, Venture Capital and Private Equity Principals | Serena Startup accelerator & VC, Venture Capital and Private Equity Principals | Not capitalistic Not partnership Event 3 Aug 2018 | | |
 Agoranov Startup accelerator & VC, Technology, Information and Internet | Agoranov Startup accelerator & VC, Technology, Information and Internet | Not capitalistic Partnership Event 5 Mar 2020 28 Feb 2025 | | |
 EuraTechnologies Startup accelerator & VC, IT Services and IT Consulting | EuraTechnologies Startup accelerator & VC, IT Services and IT Consulting | Not capitalistic Not partnership Event 17 Dec 2019 | | |
 Hello Tomorrow Trade show, Business Consulting and Services | Hello Tomorrow Trade show, Business Consulting and Services | Not capitalistic Not partnership Event 18 Mar 2024 | | |
 Cap Digital Public business cluster, French Cluster, IT Services and IT Consulting | Cap Digital Public business cluster, French Cluster, IT Services and IT Consulting | Not capitalistic Not partnership Event 24 May 2018 | | |
 Région Ile de France National and local authorities, Government Administration | Région Ile de France National and local authorities, Government Administration | Not capitalistic Partnership Event 24 May 2018 | | |
🌍 We are excited to announce that Yann Gaston-Mathe, CEO and Co-founder of iktos, will be attending the LSX World Congress 2025 in London 🇬🇧 — one of the premier global forums connecting leaders in life sciences, biotech, and healthcare investment.
🎤 As a featured speaker, Yann will present Iktos’ AI technology for drug discovery, and share how our unique approach to data-driven de novo design is accelerating the development of novel, high-quality therapeutic candidates.
📌 Join us in London from April 28 to 30 to hear how Iktos is reshaping the future of small molecule drug discovery through generative AI and machine learning.
🤝 Looking to connect at the event? Don’t hesitate to reach out — we’d love to meet! https://lnkd.in/ddbtpquX
#LSXWorld #DrugDiscovery #AIDD #GenerativeAI #Pharma #Biotech #DeNovoDesign #MachineLearning
🧬 Targeting ATIP3-deficient Breast Cancers: A Step Toward Personalized Therapies 🎯 We are proud to share the latest scientific contribution of Alexis Denis, SVP Head of Drug Discovery and Marie Varin de Lapeyriere, Senior Scientist Medicinal Chemistry at iktos, who have co-authored a newly published study in Cancer Letters uncovering promising therapeutic avenues for ATIP3-deficient breast cancers—an aggressive cancer subtype with limited treatment options and poor prognosis.
📄 Key Findings:
🔹 ATIP3-deficient breast cancers are highly sensitive to WEE1 inhibition.
🔹 WEE1 inhibition triggers mitotic catastrophe in ATIP3-deficient cells.
🔹 DNA2 helicase contributes to chromosome pulverization upon WEE1 inhibition.
🔹 Dual WEE1/PKMYT1 inhibition enhances therapeutic efficacy in ATIP3-deficient tumors.
🔬 These findings offer strong preclinical support for the clinical exploration of WEE1-targeted therapies, alone or in combination with PKMYT1 inhibitors, as a personalized medicine strategy for patients with ATIP3-deficient breast cancer.
👉 To learn more: https://lnkd.in/eeHErKbB
👏 Congratulations to the team for their impactful work pushing the boundaries of translational cancer research! Maria Haykal, Sylvie Rodrigues-Ferreira, Rania EL BOTTY, Laura Sourd, Elisabetta Marangoni, Clara Nahmias
Gustave Roussy Université Paris-Saclay Inovarion Institut Curie
#CancerResearch #BreastCancer #PrecisionOncology #DrugDiscovery #WEE1 #PKMYT1 #ATIP3 #TargetedTherapies #CancerLetters
Can you achieve 80%+ success rates from hit identification to lead optimization? 🔬 With virtual DMTA cycles, only make and test the best compounds—saving time and resources, and maximizing success rates 🚀.
Our proven AI tools:
🧬 Makya: Generative AI for molecule design
🛠️ Spaya: AI-powered retrosynthesis
✔️ Ligand- and structure-based drug design and optimization, easy to synthesize in the lab!
✔️ Seamless integration into your discovery workflows.
Whether you're looking to deliver faster results, differentiate your discovery services, or win more projects, reach out to our team to learn what is possible!
👉 https://iktos.ai/contact
#AIDrugDiscovery #CRO #MedicinalChemistry #DMTA
Can you achieve 80%+ success rates from hit identification to lead optimization? 🔬 With virtual DMTA cycles, only make and test the best compounds—saving time and resources, and maximizing success rates 🚀.
Our proven AI tools:
🧬 Makya: Generative AI for molecule design
🛠️ Spaya: AI-powered retrosynthesis
✔️ Ligand- and structure-based drug design and optimization, easy to synthesize in the lab!
✔️ Seamless integration into your discovery workflows.
Whether you're looking to deliver faster results, differentiate your discovery services, or win more projects, reach out to our team to learn what is possible!
👉 https://iktos.ai/contact
#AIDrugDiscovery #CRO #MedicinalChemistry #DMTA
📣 Heading to San Diego for Drug Discovery Chemistry 2025? So are we! We’re excited to share that our colleagues Philip Laut and Matthew Medcalf will be representing iktos at this year’s conference, taking place April 14–17.
🤖 Visit us at Booth (311) to learn more about how our AI-driven solutions are accelerating drug discovery.
🚨 Don’t miss our scientific poster presentation (B21), where we’ll be showcasing our latest innovations in generative AI and molecular design.
If you’re attending, we’d love to connect—come say hello!
👉https://lnkd.in/gkhkep5
#DrugDiscoveryChemistry #AIinDrugDiscovery #AIDD #Makya #Spaya #GenerativeAI #MedChem #Robotics #DDC2025 #SanDiego #DrugDiscovery